[go: up one dir, main page]

NO934777D0 - Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cell elinje - Google Patents

Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cell elinje

Info

Publication number
NO934777D0
NO934777D0 NO934777A NO934777A NO934777D0 NO 934777 D0 NO934777 D0 NO 934777D0 NO 934777 A NO934777 A NO 934777A NO 934777 A NO934777 A NO 934777A NO 934777 D0 NO934777 D0 NO 934777D0
Authority
NO
Norway
Prior art keywords
cell line
monoclonal antibody
tumor
antigen specific
specific monoclonal
Prior art date
Application number
NO934777A
Other languages
English (en)
Other versions
NO315472B1 (no
NO934777L (no
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Kabi Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharma Ab filed Critical Kabi Pharma Ab
Publication of NO934777D0 publication Critical patent/NO934777D0/no
Publication of NO934777L publication Critical patent/NO934777L/no
Publication of NO315472B1 publication Critical patent/NO315472B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19934777A 1991-07-03 1993-12-22 Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk NO315472B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Publications (3)

Publication Number Publication Date
NO934777D0 true NO934777D0 (no) 1993-12-22
NO934777L NO934777L (no) 1994-02-11
NO315472B1 NO315472B1 (no) 2003-09-08

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19934777A NO315472B1 (no) 1991-07-03 1993-12-22 Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk

Country Status (19)

Country Link
US (1) US5552293A (no)
EP (1) EP0521842B1 (no)
JP (1) JP3194020B2 (no)
KR (1) KR100246681B1 (no)
AT (1) ATE171193T1 (no)
AU (2) AU2292092A (no)
CA (1) CA2073124C (no)
DE (1) DE69226990T2 (no)
DK (1) DK0521842T3 (no)
EE (1) EE03031B1 (no)
ES (1) ES2124250T3 (no)
FI (1) FI109207B (no)
HU (2) HU218084B (no)
IE (1) IE80841B1 (no)
IL (1) IL102390A (no)
NO (1) NO315472B1 (no)
NZ (1) NZ243435A (no)
SE (1) SE9102074D0 (no)
WO (2) WO1993001302A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
DK1411962T3 (da) 2001-03-15 2011-04-04 Neogenix Oncology Inc Terapi for pancreacancer med monoklonalt stof
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
NZ537610A (en) * 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004240541B2 (en) 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
EP2468304A3 (en) 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP2009505640A (ja) * 2005-08-11 2009-02-12 − ロジャーズ、アルピ マトシアン 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ716641A (en) 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
JP5644110B2 (ja) 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
CA3010678A1 (en) 2016-01-10 2017-07-20 Neotx Therapeutics Ltd. Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
KR20180105233A (ko) 2016-02-05 2018-09-27 이뮤노젠 아이엔씨 세포 결합제-세포독성제 접합체를 제조하기 위한 효율적인 방법
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
MX2021013908A (es) 2019-05-15 2022-03-11 Neotx Therapeutics Ltd Tratamiento para el cáncer.
MX2022010936A (es) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
JP3334130B2 (ja) * 1990-07-20 2002-10-15 フアルマシア・アクチエボラーグ 抗体接合体
EP0540612A1 (en) * 1990-07-20 1993-05-12 Pharmacia AB Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures

Also Published As

Publication number Publication date
AU2292092A (en) 1993-02-11
ES2124250T3 (es) 1999-02-01
WO1993001302A1 (en) 1993-01-21
WO1993001303A1 (en) 1993-01-21
DE69226990D1 (de) 1998-10-22
KR100246681B1 (ko) 2000-04-01
CA2073124A1 (en) 1993-01-04
AU658198B2 (en) 1995-04-06
NO315472B1 (no) 2003-09-08
EE03031B1 (et) 1997-08-15
FI109207B (fi) 2002-06-14
DE69226990T2 (de) 1999-03-25
IL102390A0 (en) 1993-01-14
HU9400011D0 (en) 1994-05-30
HU218084B (hu) 2000-05-28
EP0521842A2 (en) 1993-01-07
CA2073124C (en) 2007-06-19
EP0521842B1 (en) 1998-09-16
JP3194020B2 (ja) 2001-07-30
FI935970A0 (fi) 1993-12-31
JPH05276987A (ja) 1993-10-26
NO934777L (no) 1994-02-11
SE9102074D0 (sv) 1991-07-03
IE80841B1 (en) 1999-03-24
HUT71193A (en) 1995-11-28
ATE171193T1 (de) 1998-10-15
IL102390A (en) 1996-01-19
US5552293A (en) 1996-09-03
NZ243435A (en) 1994-10-26
EP0521842A3 (no) 1994-01-26
HU211512A9 (en) 1995-11-28
DK0521842T3 (da) 1999-06-14
FI935970L (fi) 1993-12-31
AU1942592A (en) 1993-01-07
IE922188A1 (en) 1993-01-13

Similar Documents

Publication Publication Date Title
NO934777L (no) Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
NZ222309A (en) Antibodies (including chimeric antibodies) to a human tumour antigen, polynucleotides encoding them, detection of the antigen by immunoassay and imaging methods and also cell killing methods
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GR3029774T3 (en) Method of preparing a radioactive rhenium complex solution.
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
DE3684211D1 (no)
IT7920789A0 (it) Metodo e mezzo per regolare l'uniformita' dello stiramento di nastri.
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
EP0218158A3 (en) Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
DE3688204D1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3854926D1 (de) Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
ES2053507T3 (es) Un metodo para producir anticuerpos lym-2.
DK182188A (da) Humant tumorassocieret antigen
NO884472D0 (no) Antistoffer og fremgangsmaater for fremstilling derav.
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.
DK49685A (da) Fremgangsmaade til fremstilling af en modificeret levende pasteurella haemolytica vaccine
IT8720723V0 (it) Apparecchiatura per il controllo dell'umidita' del terreno per colture in genere.